Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Min-Su Kang, Tomoyuki Satake et al.|European Journal of Cancer|2024Cited by 47
Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective AnalysisGiulia Galli, Michele Del Vecchio, Stefano Cavalieri et al.|Oncology Research and Treatment|2019Cited by 25
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International CentersMargherita Rimini, Su Yung‐Yeh, Lorenzo Fornaro et al.|Liver International|2025Cited by 10
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast CancerMarianna Sirico, Daniele Generali, Ottavia Bernocchi et al.|Cancers|2020Cited by 9
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The <scp>MAGIC</scp> ‐D IndexMara Persano, Lorenzo Fornaro, Margherita Rimini et al.|Liver International|2025Cited by 9